<DOC>
	<DOCNO>NCT02232555</DOCNO>
	<brief_summary>The purpose study investigate efficacy duloxetine versus placebo pain outpatient major depressive disorder ( MDD ) : change Brief Pain Inventory Short Form ( BPI-SF ) 24-hour average pain score baseline 8 week treatment</brief_summary>
	<brief_title>Study Evaluate Efficacy Duloxetine Outpatients With Major Depressive Disorder Pain</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient meet criterion MDD accord Diagnostic Statistic Manual mental disorder , 4th edition ( DSMIV ) criterion confirm Mini International Neuropsychiatric Interview ( MINI ) MontgomeryAsberg Depression Rating Scale ( MADRS ) score ≥20 screen baseline ( Visits 1 2 ) Patients must least one previous episode depression medical history Painful physical symptom ( PPS ) score ≥ 3 BPISF scale average pain screen baseline Patient age 18 year old screen visit CGISeverity score ≥ 4 Visits 1 2 Patients willing able comply schedule visit , test procedure require protocol Written inform consent obtain screen visit , accordance Good clinical practice ( GCP ) local regulatory requirement , prior study procedure Neuropsychiatric exclusion Lack response current episode 2 adequate course antidepressant therapy give clinically appropriate dose sufficient length time judgement investigator Any anxiety disorder primary diagnosis within past 6 month ( include panic disorder , obsessivecompulsive disorder , posttraumatic stress disorder , generalize anxiety disorder , social phobia ) . Note : Specific phobia ( i.e . agoraphobia , arachnophobia , etc . ) allow Any diagnosis bipolar disorder , schizophrenia , psychotic disorder Presence Axis II disorder , judgement investigator , would interfere compliance study protocol History serious suicide attempt patient judge serious suicidal risk opinion investigator / score &gt; 2 question 10 ( suicide ) MADRS History drug dependence , include alcohol benzodiazepine , accord DSMIV , previous year Positive urine screen drug abuse ( cannabis , benzodiazepine , barbiturate , opiate , cocaine , amphetamine ) Other medical exclusion Patients require continuous treatment analgesic ( &gt; step 2 WHO definition ) chronic pain ( &gt; 6 month ) Patients organic pain syndrome Epilepsy history seizure disorder treatment anticonvulsant medication epilepsy seizures Patients know diagnosis raise intraocular pressure risk acute narrowangle glaucoma Known diagnosis congenital galactosaemia , glucose galactose malabsorption syndrome , lactose deficiency Patients severely impair renal function , define creatinine clearance &lt; 30 mL/min ( creatinine clearance calculate central laboratory screen safety laboratory test Acute liver injury ( hepatitis ) severe ( ChildPugh Class C ) cirrhosis Abnormal initial ECG finding accord investigator 's judgement Serious medical illness clinically significant laboratory abnormality , judgement investigator , likely require medication/ intervention hospitalization course study Women childbearing potential use medically accept mean contraception engage sexual intercourse ( e.g . intrauterine device , oral contraceptive , contraceptive patch , implant , barrier device ) Women pregnant breastfeed Pharmacological exclusion Participation another clinical trial within 30 day prior screen ( Visit 1 ) Patients previously complete withdrawn study investigate duloxetine previously treat duloxetine Treatment monoamine oxidase inhibitor ( MAOI ) within 14 day prior Visit 2 potential need use MAOI within 5 day discontinuation study drug Treatment fluoxetine within 28 day prior Visit 2 Treatment exclude medication ( list Protocol ) within 7 day prior Visit 2 ( except MAOI within 14 day fluoxetine within 28 day ) Frequent and/or severe allergic reaction multiple medication . Known hypersensitivity duloxetine inactive ingredient Electroconvulsive Therapy ( ECT ) Transcranial Magnetic Stimulation ( TMS ) within one year prior screen Initiation discontinuation depressionoriented psychotherapeutic treatment ( e.g . behavioural therapy , psychoanalytic therapy , cognitive therapy etc . ) within 6 week prior screen visit plan use treatment time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>